Background {#Sec1}
==========

Gastric neuroendocrine tumors (gNETs) are rare neoplasms with significant heterogeneity that account for approximately 4.0% of all neuroendocrine tumors \[[@CR1]\], and the incidence of gNET increases yearly \[[@CR2], [@CR3]\]. According to the 2010 WHO classification, gNET can be divided into neuroendocrine tumors, neuroendocrine carcinomas and mixed neuroendocrine cancers \[[@CR3]\]. Gastric mixed adenoneuroendocrine carcinomas (gMANECs) contain gastric adenocarcinoma and neuroendocrine carcinoma cells, with each population accounting for at least 30% of tumor cells \[[@CR4]\]. The pathology of gMANEC indicates that its clinical and biological characteristics differ from those of simple gastric neuroendocrine carcinoma and simple gastric adenocarcinoma \[[@CR5]\]. However, due to the low incidence of gMANEC, few gMANEC studies have been performed, most of which analyze only a single or a few patients \[[@CR6]--[@CR8]\]. In addition, no guidelines currently exist for gMANEC patients, as the 2017 National Comprehensive Cancer Network guidelines do not address gMANEC treatment, and factors affecting gMANEC prognosis and treatment have not yet been reported. Therefore, we retrospectively investigated the clinicopathologic data of gMANEC after radical gastrectomy in a large-volume center to analyze prognostic factors and identify appropriate adjuvant treatments.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

We retrospectively analyzed clinical data from patients diagnosed with gMANEC at Union Hospital, Fujian Medical University, from January 2007 to December 2016. The inclusion criteria were as follows: (1) those pathologically diagnosed with gMANEC; (2) those without distant metastasis, as assessed by preoperative examination; and (3) those who underwent D2 lymph node dissection and for whom postoperative pathological diagnosis of R0 resection was conducted. The following were the exclusion criteria: (1) those with preoperative and intraoperative findings of distant metastasis; (2) those who underwent preoperative adjuvant chemotherapy or radiotherapy; and (3) those with incomplete clinical data. A total of 80 gMANEC patients were included in this study. The study was approved by the ethics committee of the Fujian Medical University Union Hospital. Written consent was provided by the patients for their information and specimens to be stored in the hospital database and used in research.

Diagnosis and classification of gMANEC {#Sec4}
--------------------------------------

gMANEC was defined as a malignant tumor containing a proportion of at least 30% or more of both glandular epithelial cells and neuroendocrine cells according to the 2010 classification of neuroendocrine tumors. All neuroendocrine tumors were confirmed, diagnosed and classified using microscopic histomorphological features, immunohistochemical staining for neuroendocrine tumor-associated biomarkers. The pathological findings were confirmed by two experienced pathologists.

Tumor dominance: When the tumor had not metastasized, the tumor component in the primary tumor was greater than 50% of all tumors. If lymph node metastasis occurred, the number of metastatic lymph nodes in the tumor component was greater than 50% of all metastatic lymph nodes. gMANEC was divided into the neuroendocrine carcinoma (NEC) group and the adenocarcinoma (AC) group according to the type of tumor dominance: NEC-dominant type (Fig. [1a](#Fig1){ref-type="fig"}) and AC-dominant type (Fig. [1b](#Fig1){ref-type="fig"}).Fig. 1Different components in lymph node metastasis. (**a**) adenocarcinoma component. (**b**) neuroendocrine carcinoma component. (**c**) mixed components with neuroendocrine carcinoma and adenocarcinoma

Variables and definitions {#Sec5}
-------------------------

Overall survival (OS) was recorded from the time of surgery to the last follow-up, date of death or the deadline of the follow-up database (such as lost to follow-up or other causes of death). Recurrence-free survival was the time from the first diagnosis to the initial recurrence. Post-recurrence survival was the time from the initial recurrence to the date of death. The following definitions for recurrent tumors were utilized: (1) local recurrence - gastric stump or anastomotic recurrence, metastasis to lymph nodes around the stomach; (2) hematogenous metastasis - metastasis to remote organs (e.g., the liver, lung, brain, bone) or to periaortic lymph nodes or lymph nodes outside the abdominal cavity; and (3) peritoneal recurrence - a tumor derived from the peritoneum or ovary \[[@CR9]\]. A tumor size of 5 cm was considered the cut-off point. For Ki-67, 60% positive was considered the cut-off point \[[@CR10]\].

Treatment {#Sec6}
---------

Operation: The surgical method, including radical total gastrectomy, radical distal gastrectomy and proximal gastrectomy, was selected depending on the tumor location. Lymph node dissection was performed according to Japanese gastric cancer treatment guidelines (13th edition) \[[@CR11]\].

Postoperative adjuvant chemotherapy with 5- fluorouracil (FU) was performed for patients at stage II or above.

Treatment for patients with recurrence: Patients with recurrence after postoperative adjuvant chemotherapy were treated with chemotherapy based on 5-FU plus taxol.

Statistical analysis {#Sec7}
--------------------

All of the data were analyzed using SPSS 20.0 statistical software. The χ^2^ test was used to compare count data, and the binary logistic regression model was used to analyze independent risk factors for lymph node metastasis. OS and recurrence-free survival were calculated using the Kaplan-Meier method. The log rank test was used to compare survival and recurrence rates. The Cox regression model was used for the multivariate analysis of prognosis. The pros and cons of the prognostic model were compared by combining the area under the receiver operating characteristic (ROC) curve (AUC). *P* \< 0.05 was considered a significant difference.

Results {#Sec8}
=======

Clinicopathologic characteristics {#Sec9}
---------------------------------

Eighty patients with gMANEC were enrolled in this study from January 2007 to December 2016; 44 were in the NEC group, and 36 were in the AC group. Table [1](#Tab1){ref-type="table"} shows the clinicopathologic characteristics of the entire cohort (*n* = 80). There was no significant difference between the two groups in terms of male-female ratio, American Society of Anesthesiologists (ASA) score, depth of invasion, lymph node metastasis, TNM stage or Ki-67-positive index, although the NEC group exhibited larger tumor sizes.Table 1Patient CharacteristicsNEC dominant typeAC dominant type*P* valueAge(year)0.071  \< 651621  ≥ 652815Gender0.798 Male3328 Female118ASA score0.265 12022 22010  ≥ 344Tumor size(cm)0.023  \< 52026  ≥ 52410Tumor location0.108 Upper2315 Middle48 Lower911 Diffuse82T stage0.202 T1 + T258 T32413 T41515N stage0.095 N0124 N13232TNM stage0.268 I-II115 III3331Operation types0.145 Total gastrectomy3422 Distal gastrectomy1014Surgical method0.631 Open1510 Laparoscopic2926Complication0.763 Yes85 No3631Ki-67 positive index (%)0.26  \< 601618  ≥ 602818

Lymph node metastasis {#Sec10}
---------------------

There were 64 patients of lymph node metastasis and 16 patients without lymph node metastasis. A total of 328 lymph node metastases were identified in 73% (32/44) of NEC group patients, including 297 identified as simple NEC,26 identified as simple AC, and 5 identified as mixed components containing NEC and AC (Fig. [1c](#Fig1){ref-type="fig"}). A total of 269 lymph node metastases were identified in 89% (32/36) of the AC group patients, including 223 identified as simple AC, 34 identified as simple NEC, and 12 patients of mixed components containing NEC and AC (Fig. [2](#Fig2){ref-type="fig"}). In univariate analysis, T stage (*P* = 0.004) and age \< 65 (*P* = 0.023) were associated with lymph node metastasis (Additional file [1](#MOESM1){ref-type="media"}: Table S1), and in the multivariate analysis, T stage (*P* = 0.010) and age \< 65 (*P* = 0.016) were independent risk factors for lymph node metastasis (Table [2](#Tab2){ref-type="table"}).Fig. 2The components of lymph node metastasis in the neuroendocrine carcinoma group and adenocarcinoma groupTable 2Multivariate analysis of lymph node metastasis in the entire groupBSEWaldHR95%CI*P*T stage T1 + T2 T31.8560.8884.3696.3971.123--36.4550.037 T43.8111.2858.79745.1833.642--560.5650.003Age \< 652.1370.8905.7728.4781.482--48.5840.016

Overall survival {#Sec11}
----------------

The 3-year OS for these 80 patients was 55%, with a median survival of 27 months. The 3-year survival rate of those with NEC-dominant-type tumors (40% vs. 75%, *P* = 0.006) was significantly worse than that of those with AC-dominant-type tumors (Fig. [3](#Fig3){ref-type="fig"}). According to the univariate analysis, an NEC-dominant type, a Ki-67-positive index ≥60%, and tumor size ≥5 cm were associated with poor OS. NEC dominance and Ki-67 positivity ≥60% were independent risk factors for OS in the multivariate analysis (Table [3](#Tab3){ref-type="table"}).Fig. 3Kaplan-Meier survival curves for overall survival according to types of tumor dominance (NEC: neuroendocrine carcinoma; AC: adenocarcinoma)Table 3Univariable and multivariable Cox regression analyses of OSUnivariableMultivariable*n*3-year OS (%)*P* valueHR95% CI*P* valueAge(year)0.738  \< 653754  ≥ 654349Gender0.74 Male6151 Female1956ASA score0.28 14259 23049  ≥ 3833Tumor size (cm)0.0431.5370.799--2.9590.198  \< 54664  ≥ 53435Tumor location0.288 Upper3850 Middle1275 Lower2051 Diffuse1036T stage0.288 T1 + T21381 T33758 T43036N stage0.327 N01666 N16449TNM stage0.235 I-II1665 III6749Operation types0.795 Total gastrectomy5652 Distal gastrectomy2453Surgical method0.084 Open2537 Laparoscopic5560Complication0.647 Yes1362 No6751Ki-67positive index (%)0.0022.5951.242--5.4250.011  \< 603473  ≥ 604637tumor component in the primary tumor0.683 AC higher3451 NEC higher4644Tumor domination0.0062.2081.078--4.5200.03 AC dominant type3668 NEC dominant type4445Adjuvant chemotherapy0.404 Yes5057 No3039

Recurrence-free survival {#Sec12}
------------------------

The median follow-up time was 42 months. The 3-year recurrence-free survival was 49%, and the median recurrence-free survival was 19 months. Patients with NEC-dominant-type tumors exhibited decreased recurrence-free survival compared to those with AC-dominant-type tumors (33% vs. 68%, *P* = 0.025), as shown in Fig. [4a](#Fig4){ref-type="fig"}. In addition, post-recurrence survival was significantly better for AC-dominant-type patients (10 months vs. 6 months, *P* = 0.042) (Fig. [4b](#Fig4){ref-type="fig"}). Among those with NEC-dominant-type tumors, recurrence occurred in 26 patients (60%), consisting of hematogenous recurrence in 17 (65%), peritoneal recurrence in 6 (23%) and local recurrence in 3 (12%). Among the AC-dominant-type patients, recurrence occurred in 13 (36%), including hematogenous recurrence in 7 (54%) and peritoneal recurrence in 6 (46%); this group had no local recurrence. Univariate and multivariate analyses revealed NEC dominance and a Ki-67-positive index ≥60% to be independent risk factors for gMANEC recurrence (Table [4](#Tab4){ref-type="table"}).Fig. 4Relationship between types of tumor dominance (NEC: neuroendocrine carcinoma; AC: adenocarcinoma) and prognosis. (**a**) Kaplan-Meier survival curves for recurrence-free survival; (**b**) Kaplan-Meier survival for curves survival time after recurrenceTable 4Univariable and multivariable Cox regression analyses of RFSUnivariableMultivariable*n*recurrence*P* valueHR95% CI*P* valueAge(year)0.663  \< 653722  ≥ 654317Gender0.915 Male6129 Female1910ASA score0.377 14218 23017  ≥ 384Tumor size (cm)0.555  \< 54622  ≥ 53417Tumor location0.119 Upper3818 Middle123 Lower2011 Diffuse107T stage0.08 T1 + T2134 T33716 T43019N stage0.182 N0165 N16434TNM stage0.249 I-II166 III6733Operation types0.381 Total gastrectomy5625 Distal gastrectomy2414Surgical method0.162 Open2514 Laparoscopic5525Complication0.081 Yes137 No6732Ki-67positive index (%)0.0261.9791.012--3.8700.046  \< 603414  ≥ 604625tumor component in the primary tumor0.751 AC higher3416 NEC higher4623Tumor domination0.0251.9931.016--3.9090.045 AC dominant type3613 NEC dominant type4426Adjuvant chemotherapy0.807 Yes5027 No3012

ROC curve prediction of OS and recurrence-free survival {#Sec13}
-------------------------------------------------------

The discriminative power of the predictive model was expressed as the AUC comparing the degree of similarity between the predicted and actual values. For the 3-year OS, the AUC was 0.574, 0.642 and 0.644 using TNM staging, tumor proportion and the Ki-67-positive index, respectively, with a combined AUC of 0.727 (Fig. [5a](#Fig5){ref-type="fig"}). For 3-year recurrence-free survival, the AUC was 0.561, 0.614 and 0.564 using TNM staging, tumor fraction, and Ki-67-positive index, respectively, with a combined AUC of 0.657 (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5Area under the receiver operating characteristic (ROC) curve of different prognostic factors. (**a**) ROC curve for overall survival; (**b**) ROC curve recurrence-free survival

The impact of tumor dominance on chemotherapy efficacy {#Sec14}
------------------------------------------------------

Fifty patients (60%) received 5-FU-based adjuvant chemotherapy; 30 patients did not. There were no differences in OS and recurrence-free survival between patients that received chemotherapy and those that did not (median OS, 28 vs. 22 months, *P* = 0.404; median recurrence-free survival, 14 vs. 15 months, *P* = 0.807) (Fig. [6a, b](#Fig6){ref-type="fig"}). Patients in the AC group treated with adjuvant chemotherapy had a significantly better OS than those that did not receive chemotherapy (median OS, 43 vs. 13 months, *P* = 0.026) (Fig. [6c](#Fig6){ref-type="fig"}). In contrast, patients treated with adjuvant chemotherapy in the NEC group had a similar OS to those who did not receive chemotherapy (median OS, 19 vs. 29 months, *P* = 0.398) (Fig. [6d](#Fig6){ref-type="fig"}).Fig. 6Relationship between adjuvant chemotherapy and prognosis. (**a**) Comparison of overall survival between patients with adjuvant chemotherapy and patients without adjuvant chemotherapy. (**b**) Comparison of recurrence-free survival between patients with adjuvant chemotherapy and patients without adjuvant chemotherapy. (**c**) Comparison of effects of adjuvant chemotherapy and non-chemotherapy on overall survival in adenocarcinoma-dominant-type patients. (**d**) Comparison of effects of adjuvant chemotherapy and non-chemotherapy on overall survival in neuroendocrine carcinoma-dominant-type patients

Discussion {#Sec15}
==========

There are two hypotheses regarding the origin of gMANEC. The first postulates that AC cells differentiate into neuroendocrine cancer cells \[[@CR12]\]; the second posits that monoclonal pluripotent stem cells differentiate into two types of cells \[[@CR13], [@CR14]\]. Patients with AC and NEC not only have different prognoses but receive different treatments \[[@CR15]\]. Previous research revealed that the clinical features of gMANEC largely depend on the proportion of neuroendocrine cancer components \[[@CR16], [@CR17]\]. Fernandes et al. conclude that gMANEC prognosis depends on the more aggressive component \[[@CR18]\]. Among 21 gMANEC patients, the proportion of primary tumor components was revealed to be an independent prognostic factor, with a higher rate of NEC component indicating a worse prognosis \[[@CR19]\]. In lymph node metastasis-negative (N-) gMANEC, the tumor component present in a higher proportion of the primary tumor suggests the predominant tumor growth. In this study, gMANEC was grouped according to the ratio of primary tumor components in N- patients. For example, if the tumor was more than 50% AC, it was considered the AC-dominant type. In lymph node positive (N+) gMANEC, we found that the composition of the primary tumor was not a factor influencing lymph node metastasis, indicating that tumor components in the primary tumor do not fully reflect malignancy in N+ patients. Therefore, positive lymph nodes in every patient were calculated, and the metastatic components from each positive lymph node were identified. If the lymph node metastases contained more than 50% AC components in N+ patients, the patient was placed in the AC-dominant type group; otherwise, the patient was classified with the NEC-dominant type. For example, if a patient had 10 positive lymph nodes, including 6 simple AC components, 4 simple NEC components, indicating that AC components were 60% (more than 50%); this patient would be placed into the AC group. Thus, gMANEC was divided into two groups: AC and NEC. By comparing OS and recurrence-free survival between these groups, we revealed that this typing method exhibits good prognostic differentiation.

Accurate prognostic prediction is crucial for patients with gMANEC who undergo radical surgery. However, the ability of TNM staging to predict prognosis in those with NEC remains controversial \[[@CR20], [@CR21]\]. To our knowledge, whether TNM staging accurately predicts gMANEC prognosis has not been reported. In this study, discriminatory power was limited when using TNM staging to predict gMANEC prognosis (predicted AUC of 0.574 for 3-year OS and 0.561 for 3-year recurrence-free survival). Therefore, we established a prognostic model based on TNM staging combined with the tumor composition ratio and Ki-67 index to provide a reference for identifying patients with a poor prognosis. The model included only two postoperative pathological indicators, which are simple and easily obtained by routine postoperative pathological examination. Overall, the predictive model had good discriminatory ability. The AUCs of the 3-year OS and 3-year recurrence-free survival were 0.727 and 0.657, respectively.

There is no uniform regimen for adjuvant chemotherapy to treat gMANEC. An irinotecan plus cisplatin regimen has yielded good results for NEC \[[@CR22]\]. However, Shen et al. used irinotecan plus cisplatin and cisplatin plus etoposide as adjuvant chemotherapy to treat postoperative gMANEC and NEC and showed a similar prognosis between the chemotherapy and non-chemotherapy groups, suggesting that postoperative chemotherapy has no benefit. Accordingly, platinum-based chemotherapy has been recommended as a first-line treatment for gMANEC. In our study, the OS of patients in the AC group treated with adjuvant chemotherapy was significantly better than that of patients that did not receive chemotherapy (median survival time 43 months vs. 13 months, *P* = 0.026), whereas there was no OS advantage for patients in the NEC group that received adjuvant chemotherapy (median survival time 19 months vs. 29 months, *P* = 0.398). Post-recurrence survival among patients in the AC group was also significantly longer than in the NEC group (10 months vs. 6 months, *P* = 0.042). These results indicate that patients in the AC group may benefit from 5-FU-based chemotherapy, which is a popular choice to treat AC.

To our knowledge, this study is the first large-scale study to independently investigate gMANEC prognosis and recurrence. Notably, we classified tumors into the NEC group and the AC group according to gMANEC pathological features. Our results revealed that adjuvant chemotherapy based on 5-FU only benefitted patients in the AC group, suggesting that the clinical modality of gastric AC may be more suitable for AC-dominant-type gMANEC and providing a basis for individualized gMANEC treatment.

This study has several limitations. 1. There is a certain selection bias due to the single-center, retrospective nature of the study. 2. The data are from Eastern countries, with a lack of external verification data, especially from Western countries; thus, multi-center, prospective, large-sample analyses are needed for confirmation of the results.

Conclusion {#Sec16}
==========

Presence of NEC-dominant disease and a Ki-67-positive index ≥60% were significantly associated with worse survival and a higher recurrence rate in gMANEC patients. NEC patients may benefit from receiving gastric adjuvant chemotherapy treatments.

Additional file
===============

 {#Sec17}

Additional file 1:**Table S1.** Univariate analysis of lymph node metastasis in the entire group. In this univariate analysis, T stage (*P* = 0.004) and age \< 65 (*P* = 0.023) were associated with lymph node metastasis. (DOCX 17 kb)
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